Skip to main content

9 Result(s)

within Paula Cramer Remove this filter

and

  1. Article

    Open Access

    Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group

    Idelalisib in combination with rituximab is an efficacious treatment for patients suffering from chronic lymphocytic leukemia (CLL) with known limitations due to toxicities. However, the benefit after prior B...

    Julia von Tresckow, Nikola Heyl, Sandra Robrecht, Adam Giza… in Annals of Hematology (2023)

    Download PDF (702 KB) View Article

  2. Article

    Open Access

    Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial

    Julia von Tresckow, Paula Cramer, Sandra Robrecht, Petra Langerbeins… in Leukemia (2022)

    Download PDF (432 KB) View Article

  3. No Access

    Article

    Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

    Moritz Fürstenau, Georg Hopfinger, Sandra Robrecht, Anna-Maria Fink… in Leukemia (2020)

  4. Article

    Open Access

    The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

    Karl-Anton Kreuzer, Richard R. Furman, Stephan Stilgenbauer, Ronald L. Dubowy… in Leukemia (2020)

    Download PDF (652 KB) View Article

  5. No Access

    Article

    Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

    In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we desc...

    Silvia Maria Lavezzi, Jan de Jong, Martine Neyens, Paula Cramer… in Pharmaceutical Research (2019)

  6. No Access

    Article

    CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

    Obinutuzumab (GA101) and ibrutinib show excellent efficacy for treatment of chronic lymphocytic leukemia (CLL). Preclinical investigations and a complementary safety profile were in support of testing their co...

    Julia von Tresckow, Paula Cramer, Jasmin Bahlo, Sandra Robrecht… in Leukemia (2019)

  7. Article

    Open Access

    Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

    Deciphering the evolution of cancer cells under therapeutic pressure is a crucial step to understand the mechanisms that lead to treatment resistance. To this end, we analyzed whole-exome sequencing data of ei...

    Carmen D. Herling, Nima Abedpour, Jonathan Weiss, Anna Schmitt… in Nature Communications (2018)

    Download PDF (822 KB) View Article

  8. No Access

    Article

    New therapeutic targets and treatment strategies

    2011 saw improvements in our understanding of B-cell malignancies: insights into the genomic basis of chronic lymphocytic leukemia were achieved; reduced treatment intensity caused fewer toxic effects in early...

    Paula Cramer, Michael Hallek in Nature Reviews Clinical Oncology (2012)

  9. No Access

    Article

    Prognostic factors in chronic lymphocytic leukemia—what do we need to know?

    Chronic lymphocytic leukemia (CLL) can present as an acute leukemia that is aggressive and life threatening or in an indolent form that will not require treatment over decades. A number of methods are availabl...

    Paula Cramer, Michael Hallek in Nature Reviews Clinical Oncology (2011)